# PTX-200 and Carboplatin in Ovarian Cancer

> **NCT01690468** · PHASE1,PHASE2 · TERMINATED · sponsor: **Prescient Therapeutics, Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Triciribine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01690468
- **Lead sponsor:** Prescient Therapeutics, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Enrollment stopped prior to Phase 1b, change in strategic focus
- **Last updated:** 2020-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01690468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01690468, "PTX-200 and Carboplatin in Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01690468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*